Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35

Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $28 to $35.